|
| 微小RNA-21评估结肠癌Ⅱ期患者预后价值的meta分析 |
| Prognostic value of miR-21 in stage II colon cancer: a meta-analysis |
| 投稿时间：2016-12-10 |
| DOI：10.3969/j.issn.1000-0399.2017.10.007 |
| 中文关键词: 结肠癌 微小RNA-21 预后 meta分析 |
| 英文关键词: Colon cancer miR-21 Prognosis Meta-analysis |
| 基金项目:安徽省科技计划项目（项目编号：3101005002598） |
|
| 摘要点击次数: 2408 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探究微小RNA-21能否成为预测结肠癌Ⅱ期患者预后的分子标志物，为临床决策提供参考。方法 在PubMed、Web of Science、EMBASE和CNKI电子数据库中检索关于微小RNA-21与结肠癌Ⅱ期患者预后关系的研究，采用Review Manager 5.3和Stata 12.0软件进行meta分析。结果 共纳入8篇文献，包括1 533例结肠癌Ⅱ期患者。对于微小RNA-21与结肠癌Ⅱ期患者总生存期和无病生存期的研究中，采用固定效应模型计算合并风险比及95%置信区间分别为1.43（1.28～1.60）与2.76（1.71～4.47），且微小RNA-21高表达组与低表达组患者预后状态的差异均具有统计学意义（P<0.05）。结论 高表达微小RNA-21是结肠癌Ⅱ期患者的危险因素，作为评估结肠癌Ⅱ期患者预后分子标志物可能存在研究价值。 |
| 英文摘要: |
| Objective To elucidate whether miR-21 as a molecular biomarker can predict the prognosis of patients with stage Ⅱ colon cancer or not.Methods wide range of databases (PubMed, Web of Science, EMBASE and CNKI) for miR-21 expression associated with prognosis of stage Ⅱ colon cancer patientswere searched. Review Manager 5.3 and Stata12.0 were used to calculate the pooled effect values.Results Eight studies including a total of 1533 patients with stage Ⅱ colon cancer were enrolled. The pooled hazard ratio value of disease free survival and overall survival correlated with miR-21expression in stage Ⅱ colon cancer patients were 1.43(1.28-1.60) and 2.76 (1.71-4.47), respectively. Moreover, the difference between high expression group and low related to prognosis of patients was statistically significant(P<0.05)..Conclusion Highly expressed miR-21 is an independent risk factorof colon cancer, which may serve as a promising prognostic molecular biomarker in stage Ⅱ colon cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
